Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC)

Lorenzen, Sylvie; Knorrenschild, Jorge Riera; Pauligk, Claudia; Hegewisch-Becker, Susanna; Seraphin, Joerg; Thuss-Patience, Peter; Kopp, Hans-Georg; Dechow, Tobias; Vogel, Arndt; Luley, Kim Barbara; Pink, Daniel; Stahl, Michael; Kullmann, Frank; Hebart, Holger; Siveke, Jens; Egger, Matthias; Homann, Nils; Probst, Stephan; Goetze, Thorsten Oliver; Al-Batran, Salah-Eddin

Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC)

Author:

Lorenzen, Sylvie; Knorrenschild, Jorge Riera; Pauligk, Claudia; Hegewisch-Becker, Susanna; Seraphin, Joerg; Thuss-Patience, Peter; Kopp, Hans-Georg; Dechow, Tobias; Vogel, Arndt; Luley, Kim Barbara; Pink, Daniel; Stahl, Michael; Kullmann, Frank; Hebart, Holger; Siveke, Jens; Egger, Matthias; Homann, Nils; Probst, Stephan; Goetze, Thorsten Oliver; Al-Batran, Salah-Eddin

Tübinger Autor(en):

Kopp, Hans-Georg

Published in:

International Journal of Cancer (2020), Bd.

Verlagsangabe:

Wiley

Language:

English

Full text:

http://dx.doi.org/10.1002/ijc.33025

ISSN:

1097-0215